Meet Coreline Soft at Journées de Printemps de la Société d'Imagerie Thoracique (SIT 2026)
Coreline Soft will participate in SIT 2026 (Journées de Printemps de la Société d'Imagerie Thoracique), one of France's leading meetings dedicated to thoracic imaging.
As lung cancer screening continues to expand across Europe, discussions are increasingly shifting beyond AI detection performance toward large-scale implementation, workflow integration, and long-term patient management.
At SIT 2026, Coreline Soft will share real-world experience from national lung cancer screening initiatives, including France's rapidly expanding IMPULSION program.
From AI Detection to Screening Infrastructure
The future of lung cancer screening is no longer defined solely by finding nodules.
Successful population-based screening programs require:
• Consistent detection quality
• Structured reporting
• Longitudinal follow-up
• Multi-center coordination
• Scalable workflow management
These operational requirements are becoming increasingly important as screening programs move from pilot studies to national implementation.
IMPULSION: Scaling Lung Cancer Screening Across France
Only two weeks after the launch of the IMPULSION program, 35 participating screening centers were already equipped with AVIEW LCS Plus.
The program represents one of France's most important public health initiatives in lung cancer screening and reflects a broader European trend toward structured, population-based screening models.
According to Professor Marie-Pierre Revel, three key factors contributed to the selection of AVIEW LCS Plus:
• Proven pulmonary nodule detection performance
• European-based infrastructure supporting healthcare data sovereignty
• Expanded preventive assessment capabilities, including coronary artery calcification (CAC) analysis and cardiovascular risk evaluation
Beyond cancer detection, the program highlights the growing value of extracting multiple clinically relevant biomarkers from a single low-dose CT examination.
Looking Beyond Positive Findings
One observation emphasized by Professor Revel was the ability to identify very small pulmonary abnormalities that may not qualify as positive screening findings but can serve as important reference points during annual follow-up examinations.
As national screening programs mature, longitudinal patient management is becoming just as important as initial detection.
This shift is driving increased demand for quantitative imaging, structured reporting, and AI-supported follow-up workflows.
What Coreline Soft Will Showcase at SIT 2026
At SIT 2026, Coreline Soft will present its AI-powered thoracic imaging portfolio, including:
AVIEW LCS Plus
• Pulmonary nodule detection
• Quantitative analysis
• Volume and VDT assessment
• Longitudinal follow-up support
• Multi-Disease Analysis
A single chest CT can provide insights into:
• Lung cancer risk
• COPD and emphysema
• Coronary artery calcification (CAC)
• Cardiovascular risk indicators
This approach supports a broader preventive healthcare model and helps maximize the clinical value of every CT examination.
Supporting the Next Phase of Lung Cancer Screening
France's IMPULSION program is expected to continue expanding, with a goal of exceeding 100 participating centers by the end of 2026.
As national screening programs grow, the focus is increasingly moving from standalone AI software toward operational infrastructure capable of supporting quality assurance, follow-up management, and multi-center collaboration.
Coreline Soft remains committed to supporting this transformation through clinically validated AI solutions and scalable screening workflows.
Meet Coreline Soft at SIT 2026
Join us at SIT 2026 to discuss:
• Lung cancer screening implementation
• Quantitative thoracic imaging
• Multi-disease analysis
• AI-supported follow-up workflows
• National screening program scalability
